HEREDITARY ANGIOEDEMA (HAE)

This study followed 48 people with hereditary angioedema (HAE) types I and II who were treated with lanadelumab through a Polish national drug program. Researchers tracked how many patients remained free of swelling attacks over 24 months, how many attacks required rescue medicat…

This study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab to see how well it works in real life. Participants reported their swelling attacks using a smartphone app and during routine doctor visits for up to three years. The main goal was…

This study tested a monthly injection called garadacimab to prevent sudden swelling attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal was to see if the drug is safe and reduces how often attacks happen. 22 children took part, and researchers tracked side…

This study looked at 115 Chinese people with hereditary angioedema (HAE) to see how well two approved medicines work in real life. One medicine, lanadelumab, is used to prevent attacks, and the other, icatibant, is used to stop attacks once they start. Researchers checked medical…

This study looked at the safety and effectiveness of Firazyr (icatibant) for treating sudden swelling attacks in children (ages 2-17) with hereditary angioedema (HAE). Researchers tracked side effects and how quickly symptoms improved after the injection. The study involved 32 ch…

This study tested a drug called icatibant (Icanticure) in 5 adults with a rare condition that causes sudden, painful swelling attacks. The drug is already approved for hereditary angioedema, but this study aimed to gather more safety and effectiveness data for patients who couldn…

This completed French survey studied the burden of on-demand treatment for hereditary angioedema (HAE) attacks from the perspective of 300 patients and their caregivers. It collected information on attack frequency, severity, treatment delays, and impacts on quality of life, soci…